Exor: how the Agnelli family rebuilt a crisis-era conglomerate into a global holding company

Executive overview

Exor began as a vehicle for managing the Agnelli family's stake in a struggling Fiat, which had burned through four CEOs in three years and nearly failed in the early 2000s. Under John Elkan, the group transformed: selling assets, simplifying its structure, and concentrating around a shortlist of global businesses. Today Exor holds roughly 45 billion euros in gross assets, dominated by Ferrari, Stellantis, CNH, and Philips.

The holding company trades at a 50-60% discount to NAV — management treats this as an opportunity to buy back stock, not a problem to complain about.

The core discipline is duality: entrepreneurial ambition backed by a rock-solid balance sheet, with debt kept permanently between 10-20% of assets.

Three leaders who built the group

• Giovanni Agnelli (founder): built Fiat from startup to industrial conglomerate; senator in Italy for over two decades.
• Gianni Agnelli (grandson): ran Fiat for ~40 years; formed the Ferrari partnership; turned the company global.
• John Elkan (today): inherited leadership at 21 after a family tragedy; took full control at 27; restructured the entire group under the Exor umbrella and moved legal HQ to the Netherlands for tax efficiency.
• Elkan's first major move was hiring Sergio Marchionne as CEO — an outsider who secured $2 billion from GM to cancel a put option, then led Fiat back from the brink and into its merger with Chrysler.

The portfolio today

• Ferrari: largest asset, ~25-30% of NAV; treated as a luxury brand, not a car company; Exor trimmed ~3 billion of shares in 2025 to fund buybacks and reduce over-concentration.
• Stellantis: ~10% of NAV; cyclical, capital-intensive; product of the Fiat Chrysler-Peugeot mega-merger; facing EV transition pressure and overcapacity.
• CNH Industrial: global number two in agricultural equipment after John Deere; cyclical trough; new CEO; valuation undemanding.
• Iveco: commercial trucks and defense vehicles spun off in 2022; exploring separation of the defense business; M&A chatter including potential talks with Tata Motors.
• Philips: ~20% stake; repositioned from consumer electronics to pure-play health tech; facing a product recall headwind; Exor sees it as their beachhead in healthcare.

Private and unlisted investments

• The Economist: largest single shareholder since 2015; valued partly as a strategic and reputational asset, not purely financial.
• Institut Mérieux: family-owned healthcare company covering diagnostics, vaccines, and immunotherapy; Exor's first significant step into health tech.
• Christian Louboutin: premium luxury footwear; acquired because the brand wanted patient, non-conglomerate ownership.
• Welltech: robotics and tools for the energy sector; investment made in 2016 at the bottom of the energy cycle.
• Lingotto: asset management platform launched in 2023 with ~6.4 billion AUM; grew out of the Partnere talent network; operates independently of Exor.
• Via: urban mobility company (ride-pooling optimization); Exor owns ~9%; filed a confidential IPO S1 in 2025.

The Partnere episode

• Exor acquired the reinsurance company in 2015 for ~9 billion; sold to Covea ~five years later at roughly 9-10% IRR.
• Thesis was sound: patient capital with long investment horizon should absorb volatility well, similar to Berkshire's model.
• Execution was merely decent due to elevated catastrophe losses during the holding period.
• Exit came when Covea offered a solid price and market multiples were high — they took the win.
• Outcome beyond financials: retained talent from Partnere and Covea, who helped seed the Lingotto asset management platform.

NAV discount and capital allocation

• Exor's NAV discount has been unusually wide (50-60%) for an unusually long time.
• Market scepticism reflects: (1) Ferrari appreciation may not repeat; (2) remaining assets are a mix of cyclical turnarounds; (3) family time horizon mismatches institutional holding periods.
• Management response: treat the discount as an opportunity; buy back stock instead of arguing the market is wrong.
• Governance is positive overall: clear NAV-per-share metric benchmarked to MSCI World; transparent investment framework; minor exception is Juventus, which appears to be a family passion rather than a capital-allocation decision.
• Financial discipline is non-negotiable: debt 10-20% of assets, long-duration bonds, minimal bank debt.

Strategic direction: healthcare, technology, luxury

• Luxury is largely tapped out — Ferrari and Louboutin cover the space, but independent targets at the ultra-premium end are scarce and expensive.
• Technology: building expertise through Vento (Italian seed program) and a ventures portfolio; John Elkan joined the Meta board in 2025, providing direct access to AI leadership.
• Healthcare technology is the clearest growth vector: Philips and Institut Mérieux give Exor board-level presence and domain knowledge; focus on imaging, diagnostics, genomics, and health services.
• Long-term pattern: slow, measured renewal — typically two or three intentional portfolio moves per year, not constant activity.

Key lesson from following Exor

• Decisiveness is the standout trait: when a decision is needed, make it; if it proves wrong, fix it quickly.
• Long-term investors naturally bias toward inaction; Exor's crisis origin taught Elkan that the status quo can be fatal.
• Patient capital and long time horizons are not an excuse to defer hard calls on people or assets.